JP2004531562A - ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法 - Google Patents

２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法 Download PDF

Info

Publication number
JP2004531562A
JP2004531562A JP2002591461A JP2002591461A JP2004531562A JP 2004531562 A JP2004531562 A JP 2004531562A JP 2002591461 A JP2002591461 A JP 2002591461A JP 2002591461 A JP2002591461 A JP 2002591461A JP 2004531562 A JP2004531562 A JP 2004531562A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
compound
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002591461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531562A5 (enExample
Inventor
オーウェン・ブレンダン・ウォレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004531562A publication Critical patent/JP2004531562A/ja
Publication of JP2004531562A5 publication Critical patent/JP2004531562A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2002591461A 2001-05-22 2002-05-09 ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法 Withdrawn JP2004531562A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29270401P 2001-05-22 2001-05-22
PCT/US2002/011878 WO2002094788A1 (en) 2001-05-22 2002-05-09 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods

Publications (2)

Publication Number Publication Date
JP2004531562A true JP2004531562A (ja) 2004-10-14
JP2004531562A5 JP2004531562A5 (enExample) 2005-12-22

Family

ID=23125830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002591461A Withdrawn JP2004531562A (ja) 2001-05-22 2002-05-09 ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法

Country Status (7)

Country Link
US (1) US7056931B2 (enExample)
EP (1) EP1395563B1 (enExample)
JP (1) JP2004531562A (enExample)
AT (1) ATE321754T1 (enExample)
DE (1) DE60210283T2 (enExample)
ES (1) ES2259376T3 (enExample)
WO (1) WO2002094788A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505623A (ja) * 2002-10-22 2006-02-16 グラクソ　グループ　リミテッド 神経疾患の治療において有用なヒスタミンｈ３受容体リガンドとしての二環式ベンズアミド化合物
JP2008545805A (ja) * 2005-06-13 2008-12-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 有糸分裂モータータンパク質ｅｇ５の調節剤の形態で使用されるテトラヒドロキノリン
JP2021530486A (ja) * 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
JP2007523952A (ja) 2004-02-25 2007-08-23 スミスクライン ビーチャム コーポレーション 選択的エストロゲンレセプターモジュレーターとして使用するための置換キノリン化合物
EP1778656A1 (en) * 2004-08-17 2007-05-02 Janssen Pharmaceutica N.V. Benzoxazepine derivatives as selective estrogen receptor modulators
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819637A (en) * 1971-06-23 1974-06-25 Sterling Drug Inc 1,2-diphenyl-1,2,3,4-tetrahydroquinolines
US3994902A (en) * 1971-06-23 1976-11-30 Sterling Drug Inc. Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
AU509682B2 (en) * 1975-10-28 1980-05-22 Eli Lilly And Company 2-Aroyl-3-Phenylbenzothiophene Derivatives
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JPS59124889A (ja) * 1982-12-30 1984-07-19 インタ−ナショナル　ビジネス　マシ−ンズ　コ−ポレ−ション 放電記録材
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
JPH04316557A (ja) 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5403847A (en) * 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
US5508306A (en) * 1992-11-13 1996-04-16 Synaptic Pharmaceutical Corporation Aromatic amine derivatives
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
JPH09506898A (ja) 1993-12-21 1997-07-08 イーライ・リリー・アンド・カンパニー 非ペプチドタキキニン受容体アンタゴニスト
US5446053A (en) * 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5484798A (en) 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US6479517B1 (en) 1995-02-28 2002-11-12 Eli Lilly And Company Phosphorous-containing benzothiophenes
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
US6384053B1 (en) 1995-03-10 2002-05-07 Eli Lilly And Company α-substituted-1-benzyl-napthyls
US6395755B1 (en) 1995-03-10 2002-05-28 Eli Lilly And Company Benzothiophene pharmaceutical compounds
US6391892B1 (en) 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
US6608090B1 (en) 1995-04-21 2003-08-19 Eli Lilly And Company Benzothiophenes with novel basic side chains
CA2215902A1 (en) 1995-04-21 1996-10-24 Charles David Jones Benzothiophenes with novel basic side chains
US6444688B1 (en) 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
DE69600709T2 (de) 1995-06-07 1999-03-18 Eli Lilly And Co., Indianapolis, Ind. Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
DK0842169T3 (da) 1995-06-26 2001-01-29 Lilly Co Eli Benzothiophenforbindelser
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
ES2233982T3 (es) 1995-10-31 2005-06-16 Eli Lilly And Company Diaminas antitromboticas.
WO1997017069A1 (en) 1995-11-07 1997-05-15 Eli Lilly And Company Methods for treating resistant tumors
US6432982B1 (en) 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
US5688796A (en) 1996-03-12 1997-11-18 Eli Lilly And Company Heterocyclic substituted benzothiophenes, compositions, and methods
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
EP0802183B1 (en) 1996-04-19 2001-10-10 American Home Products Corporation Estrogenic agents
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US6599920B2 (en) 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
CA2214070C (en) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
ID19392A (id) 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (en) 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
CA2214919A1 (en) * 1996-09-24 1998-03-24 Kenneth Lee Hauser Benzothiophene compounds, intermediates, processes, compositions, and methods
CA2214922A1 (en) 1996-09-27 1998-03-27 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US5948796A (en) * 1996-10-10 1999-09-07 Eli Lilly And Company Benzo B!thiophene compounds, intermediates, formulations, and methods
US5958969A (en) * 1996-10-10 1999-09-28 Eli Lilly And Company Benzo b!thiophene compounds, intermediates, formulations, and methods
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2216592C (en) 1996-10-24 2006-07-18 Brian Stephen Muehl Benzothiophene compounds, intermediates, compositions, and methods
CA2218756A1 (en) 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
IL122026A0 (en) 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
CA2287922A1 (en) 1997-04-30 1998-11-05 Eli Lilly And Company Intermediates and processes for preparing benzo[b]thiophenes
JP2001513501A (ja) 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
US6090843A (en) 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US6017914A (en) 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
WO1999019293A1 (en) 1997-10-15 1999-04-22 American Home Products Corporation Novel aryloxy-alkyl-dialkylamines
CN1309637A (zh) 1998-05-15 2001-08-22 美国家用产品公司 包含2－苯基－吲哚化合物和雌激素制剂的组合物
US6060488A (en) 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505623A (ja) * 2002-10-22 2006-02-16 グラクソ　グループ　リミテッド 神経疾患の治療において有用なヒスタミンｈ３受容体リガンドとしての二環式ベンズアミド化合物
JP2008545805A (ja) * 2005-06-13 2008-12-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 有糸分裂モータータンパク質ｅｇ５の調節剤の形態で使用されるテトラヒドロキノリン
JP2021530486A (ja) * 2018-07-12 2021-11-11 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤
JP7085056B2 (ja) 2018-07-12 2022-06-15 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤

Also Published As

Publication number Publication date
DE60210283T2 (de) 2006-11-09
US20040215018A1 (en) 2004-10-28
WO2002094788A1 (en) 2002-11-28
ATE321754T1 (de) 2006-04-15
DE60210283D1 (de) 2006-05-18
ES2259376T3 (es) 2006-10-01
EP1395563A1 (en) 2004-03-10
EP1395563B1 (en) 2006-03-29
US7056931B2 (en) 2006-06-06

Similar Documents

Publication Publication Date Title
RU2165924C2 (ru) Нафтилсодержащие соединения, фармацевтическая композиция, способ смягчения симптомов постклимактерического синдрома и других связанных с эстрогеном физиологических состояний, способы получения нафтилсодержащих соединений
JPH10506112A (ja) ベンゾチオフェン化合物、組成物、および方法
RU2167158C2 (ru) Производные нафталина или дигидронафталина, фармацевтическая композиция на их основе, способы лечения и промежуточные вещества
MXPA98000800A (en) Compounds, intermediates of naftilo and dihidronaftilo, compositions and meto
EP0835868B1 (en) 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5958916A (en) Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
JP2004531562A (ja) ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法
EP1401446B1 (en) Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
US5929090A (en) 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US7375229B2 (en) Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods
US7119206B2 (en) Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators
EP1551822B1 (en) Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them
CZ290200B6 (cs) Benzothiofenová sloučenina, meziprodukty pro její výrobu a farmaceutické prostředky tuto sloučeninu obsahující

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050509

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070323